mit 20 ml of urine (first pass urine) for PCR Amplicor and one urethral specimen was taken for culture. The order of collection of the specimens was rotated every 50 patients. Discrepant results were further analysed by a second PCR with primers directed against the C trachomatis major outer membrane protein (MOMP) and by direct fluorescent antibody (DFA). Results-After analysis of discrepancies, the adjusted sensitivity and specificity of PCR on endocervical specimens were 92X9% and 100% and the positive and negative predictive values were 100% and 99.7% respectively; on the urine samples these values were 100%, 99X1%, 100% and 99X1%, respectively.
Conclusion-These results indicate that the PCR Amplicor test is a rapid sensitive and specific assay for the detection of C trachomatis in urogenital infections and provides a non-invasive technique for screening chlamydia infection in men.
Introduction
Chlamydia trachomatis infection is one of the most prevalent sexually transmitted diseases in the world. This prevalence is generally higher in STD clinics attenders, but 5% to 20% of women attending family planning clinics may be infected. Carriage of C trachomatis may be asymptomatic in both women and men, providing a reservoir for infection. ' Recovery of C trachomatis in cell culture has been considered the most sensitive and specific standard method for diagnosis but it is quite laborious and requires cell culture facilities unavailable in many laboratories.
The polymerase chain reaction (PCR) technology developed in recent years allows the detection of small quantities of specific nucleic acids, using repeated amplification steps of a respective target sequence. PCR protocols for the detection of C trachomatis have been proposed by different authors. 2 Men were asked to submit 20 ml of urine for PCR Amplicor and one urethral specimen was taken for culture. The urine specimens were always collected prior to the urethral specimens.
All cervical specimens to be analysed by PCR were placed in 1 ml of transport medium supplied by the manufacturer and stored at 4°C prior to processing and amplification (within seven days). The urines were stored at 4°C and processed within four days.
The specimens for culture were placed into 2 Cervical specimens: the swabs specimens were placed in a sodium dodecyl sulphatebased transport tube and were processed within seven days of collection. One millilitre of specimen diluent (Amplicor, RMS) was added to the transport tube. After vortex mixing, diluted specimens were allowed to stand 15 minutes at room temperature. Then, using a micropipette with plugged tips, 50 ml was removed and mixed with 50 ml of Master Mix with AmpErase (Amplicor, RMS) containing AmpliTaq, biotinylated primers, dATP, dCTP, dGTP, dUTP and uracil-n-glycosylase (to prevent amplicon contamination). The remainder of the specimen was conserved at -200C.
Male urines were stored at + 4°C and tested within four days of collection. After storage, the urines were checked for the presence of a precipitate. If a precipitate was present, specimens were warmed at 37°C with mixing to dissolve the precipitate.
Ten millilitres of urine was transferred to a conical polypropylene tube, and centrifugated at 1500 g for 10 minutes at room temperature. The cell pellet was added to 2 ml of urine resuspension buffer and allowed to stand at room temperature for one hour. Two millilitres of urine diluent (Amplicor, RMS) was added to each tube, vortexed for 1 min and remained at ambient temperature for 10 minutes prior to PCR amplification.
Samples were subjected to 30 cycles of denaturation at 95°C and hybridisation and annealing at 600C in a TC9600 thermal cycler (Perkin Elmer, Roche). The Discrepant results If a specimen produced a PCR Amplicor result discrepant with the cell culture, the test was repeated. If a disagreement was repeatedly observed, specimens were reamplified by using PCR primers directed against the C trachomatis MOMP gene. The MOMP PCR assay utilised primers described by Sayada, et al.9: CTU (5'-ATGAAAAAACTCTTGAAATCGG-3') and CTL (5'-CAAGATI-l-TCTAGA(T/C) TTCAT(C/T)TTGTT-3').
Amplification was performed in a TC 9600 thermal cycler (Perkin Elmer), starting with one cycle of 7 minutes at 94°C and 5 minutes at 48°C, followed by 35 cycles of: denaturation, 1 min at 94°C; primer annealing, 1 min at 48°C and primer extension, 2 min at 72°C, ending with the last cycle at the temperature of 72°C for 7 minutes. PCR products were analysed by electrophoresis of 10 ml of the amplification mixture on a 1% agarose gel stained with ethidium bromide. DNA was then detected by ultraviolet light exposure. RFLP using enzyme digestion by EcoRI was used to confirm the specificity of the PCR products.
Results
Women attending STD clinic By the use of the cell culture, the prevalence of C trachomatis in the high risk group of 134 women, was found to be 8.2% (11/134) . From the 11 cell culture positive, 10 (90%) were PCR Amplicor positive (table 1) .
Two discrepant results were observed: one was positive by culture and negative by Amplicor and one was culture-negative and Amplicor-positive. The specimen which was positive by culture and negative by Amplicor, Comparison of the Amplicor Chlamydia trachomatis test and cell culture for the detection of urogenital chlamydial infections Regarding the 327 women from the two groups, the revised sensitivity, specificity, PPV and NPV of the Amplicor assay were 92-9%, 100%. 100% and 99.7% respectively.
The sensitivity and the specificity of cell culture compared with true positive samples were 92.2% and 100%. Men A total of 1 12 men attending one STD clinic in Lisbon were evaluated for C trachomatis infection by the PCR Amplicor assay for urine specimens and the results were compared with those obtained by urethral cell culture. All patients complained of urethral symptoms. The prevalence of C trachomatis by urethral culture was found to be 6.3% (7/112).
Seven specimens were Amplicor positive and culture-positive and 104 specimens were negative by both tests (table 1) . There was one discrepant result which was positive by Amplicor and negative by culture. This urine specimen, when analysed by the alternative MOMP PCR was negative. In addition, a DFA test of the urine was performed (table  2) .
After centrifugation of 200 ml of urine, 5 ml of the resultant pellet was placed on a slide and fixed with methanol and stained with C trachomatis monoclonal antibodies (Syva, Microtrak) for the detection of elementary bodies (EB). No EBs were observed. The Amplicor result was considered a false positive result.
Therefore the overall sensitivity of the PCR of the PCR assay was 100% and its specificity 99-1%; the positive and negative predictive values were respectively 100% and 99. 1%.
Discussion
Cell culture has been considered the reference standard for detection of C trachomatis on urogenital samples.
PCR protocols for the detection of C trachomatis DNA in clinical specimens have been proposed by several authors because the sensitivity of the PCR technique is estimated to be higher than that of cell culture.
The Roche Amplicor C trachomatis test is a standardised commercial assay that uses a rapid DNA amplification of the common C trachomatis cryptic plasmid and a colourimetric microwell DNA hybridisation. It is a relatively easy method to process a high volume of specimens in approximately four hours. In our study, the majority of cases gave clear results: all the 20 Amplicor positive specimens (13 cervical swabs and seven urines) yielded OD values more than 0.5, and out of the 419 Amplicor negative specimens, 410 presented OD values less than 025. Only nine specimens (seven cervical swabs and two urines) had a borderline OD value (between 0.2 and 0.5) and when retested they were all negative.
In 327 cervical specimens our results show a sensitivity of 92.9% and a specificity of 100%. Other studies reporting the evaluation of the Amplicor C trachomatis test, refer to higher sensitivity values but similar specificity."1"2
In processing 327 cervical specimens, there were no false-positive results. The Amplicor test failed to detect one culture-positive specimen and detected one true-positive specimen that was culture-negative.
In the Amplicor negative, culture-positive case, the fact that the MOMP PCR test was positive on culture transport medium excludes the possibility that the culture was false-positive. Some authors had suggested that the presence of too much DNA matrix can inhibit amplification." We have tested, after dilution, this specimen (that showed 15 or more inclusions per field) and the Amplicor result remained negative. So the probable explanation is that the false negative Amplicor specimen resulted from swab to swab variability. In this study of two populations of women the sensitivity and specificity of the Amplicor test were 92.9% and 100% respectively. These values were similar to the sensitivity and specificity values of the cell culture.
In male urine specimens, the Amplicor test was in our hands highly sensitive (100%) and specific (99. 1%), compared with urethral culture. In processing 1 12 urine specimens from symptomatic males, there was only one falsepositive Amplicor result. This specimen was negative by culture and by MOMP PCR and no EBs were observed by DFA test of urine sediment; it was considered a true negative specimen.
The sensitivity and specificity values of the Amplicor test we have obtained in symptomatic males are higher than those reported in a study that has been published in the USA. '2 These results show that the Amplicor assay for detection of C trachomatis in male urine specimens is highly sensitive and specific, providing a very useful non-invasive technique.
In conclusion, because of high sensitivity and specificity, the PCR Roche assay for C trachomatis may be a good alternative to cell culture and especially useful for diagnosis of chlamydia in low prevalence populations.
